

Date: 7th February, 2025

To,
The Manager,
Department of Corporate Services,
BSE Limited
1st Floor, Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001
Scrip Code: 506235

To,
The Manager,
Listing Department,
National Stock Exchange of India Limited
"Exchange Plaza"
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051
NSE Symbol: ALEMBICLTD

Dear Sir,

Sub: Integrated Filing (Financial) – Unaudited Financial Results for the quarter and nine months period ended on 31st December, 2024


Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 2nd January, 2025, we are submitting herewith the Integrated Filing (Financial) - Unaudited Financial Results for the quarter and nine months period ended on 31st December, 2024.


This information will also be available on the Company's website at <https://www.alembiclimited.com/#ar>

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Limited

Keval Thakkar
Company Secretary



Encl.: A/a

ALEMBIC LIMITED

Statement of Consolidated Unaudited Financial Results for the Quarter and Nine Months ended 31st December, 2024

Rs. in Lakhs

Sr. No	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2024 (Unaudited)	30.09.2024 (Unaudited)	31.12.2023 (Unaudited)	31.12.2024 (Unaudited)	31.12.2023 (Unaudited)	31.03.2024 (Audited)
1	Revenue from Operations	5,792	5,291	3,932	16,162	10,844	15,749
2	Other Income	437	6,560	223	7,193	5,273	5,477
3	Total Income	6,229	11,852	4,155	23,355	16,118	21,226
4	Expenses						
	Cost of Materials Consumed	181	141	158	608	538	862
	Cost of Construction	1,607	1,659	1,289	4,456	3,007	3,981
	Changes in Inventories of Finished Goods and WIP	-88	71	(34)	114	155	53
	Employee Benefit Expenses	656	652	558	2,081	1,748	2,303
	Finance Costs	69	67	37	185	63	111
	Depreciation and amortisation expense	269	268	266	787	636	784
	Other Expenses	797	810	794	2,264	2,125	2,864
	Total Expenses	3,490	3,669	3,067	10,496	8,272	10,957
5	Profit Before Tax (3-4)	2,739	8,183	1,088	12,859	7,846	10,269
6	Tax Expenses						
	Current Tax	268	916	(69)	1,418	578	1,002
	Deferred Tax	(138)	(465)	167	(641)	409	482
	Short / (Excess) Provision of earlier years	-	(0)	(2)	(0)	(299)	(502)
7	Net Profit after tax for the Period	2,609	7,731	992	12,083	7,158	9,287
8	Share of Associate's Profit/(Loss)	3,930	4,371	5,150	12,140	12,489	17,575
9	Net Profit/(Loss) after tax and Share of Associate's Profit/(Loss)	6,539	12,102	6,142	24,223	19,647	26,862
10	Other Comprehensive Income						
	A (i) Items that will not be reclassified to Profit or (Loss)	(2,438)	(2,794)	(1,620)	(885)	(790)	(6,855)
	(ii) Income tax relating to items that will not be reclassified to Profit or (Loss)	349	(355)	195	(497)	110	775
	B (i) Items that will be reclassified to Profit or (Loss)	54	31	25	82	74	108
11	Total Comprehensive Income/(Loss) for the Period	4,503	8,984	4,742	22,924	19,041	20,890
12	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64	5,135.64	5,135.64
13	Other Equity (excluding Revaluation Reserve)						1,85,911
14	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	2.55	4.71	2.39	9.43	7.65	10.46



Alembic Limited
Segment wise Consolidated Revenue and Results

Sr. No	Particulars	Quarter Ended			Nine Months Ended		Rs. in Lakhs
		31.12.2024 (Unaudited)	30.09.2024 (Unaudited)	31.12.2023 (Unaudited)	31.12.2024 (Unaudited)	31.12.2023 (Unaudited)	31.03.2024 (Audited)
1	Segment Revenue						
	Revenue from Operations						
	a. Active Pharmaceutical Ingredients Business	625	746	648	2,443	2,377	3,174
	b. Real Estate Business	5,167	4,546	3,285	13,719	8,468	12,574
	Total Income from Operations (Net)	5,792	5,291	3,932	16,162	10,844	15,749
2	Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)						
	a. Active Pharmaceutical Ingredients Business	199	36	101	285	238	336
	b. Real Estate Business	2,533	1,786	952	6,243	2,777	5,126
	Total	2,732	1,822	1,053	6,528	3,015	5,462
	Unallocable Income and Expenditure						
	(i) Interest Expense	(69)	(67)	(37)	(185)	(63)	(111)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	54	6,398	70	6,484	4,845	4,869
	(iii) Other Income / (Expense)	22	30	1	32	49	49
	Total Profit Before Tax	2,739	8,183	1,088	12,859	7,846	10,269
3	Segment Assets						
	a. Active Pharmaceutical Ingredients Business	18,645	18,215	18,301	18,645	18,301	18,380
	b. Real Estate Business	42,922	41,848	35,326	42,922	35,326	36,700
	c. Unallocated	1,85,654	1,84,033	1,78,713	1,85,654	1,78,713	1,77,798
	Total	2,47,221	2,44,096	2,32,341	2,47,221	2,32,341	2,32,877
4	Segment Liabilities						
	a. Active Pharmaceutical Ingredients Business	3,464	3,291	2,915	3,464	2,915	2,941
	b. Real Estate Business	10,902	12,116	8,923	10,902	8,923	7,682
	c. Unallocated	3,709	4,046	3,795	3,709	3,795	3,698
	Total	18,074	19,453	15,633	18,074	15,633	14,321

Notes:

- 1 The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- 2 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.




For Alembic Limited

Chirayu Amin
Chairman

Place : Vadodara
Date : 7th February, 2025

Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months ended 31st December, 2024

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2024 (Unaudited)	30.09.2024 (Unaudited)	31.12.2023 (Unaudited)	31.12.2024 (Unaudited)	31.12.2023 (Unaudited)	31.03.2024 (Audited)
1	Revenue from Operations	5,597	5,110	3,794	15,614	10,474	15,225
2	Other Income	425	6,559	221	7,173	5,266	5,462
3	Total Income	6,021	11,669	4,015	22,787	15,740	20,687
4	Expenses						
	Cost of Materials Consumed	181	141	158	608	538	862
	Cost of Construction	1,607	1,659	1,289	4,456	3,007	3,981
	Changes in Inventories of Finished Goods and WIP	(88)	71	(34)	114	155	53
	Employee Benefit Expenses	656	652	558	2,081	1,748	2,303
	Finance Costs	52	51	26	138	36	69
	Depreciation and amortisation expense	259	259	257	759	608	746
	Other Expenses	669	749	510	2,000	1,739	2,402
	Total Expenses	3,336	3,582	2,763	10,156	7,830	10,415
5	Profit Before Tax (3-4)	2,685	8,087	1,253	12,631	7,910	10,272
6	Tax Expenses						
	Current Tax	255	892	(43)	1,360	578	1,000
	Deferred Tax	(139)	(465)	168	(641)	411	484
	Short / (Excess) Provision of earlier years	-	(0)	(2)	(0)	(299)	(501)
7	Net Profit after tax for the Period	2,569	7,660	1,129	11,912	7,221	9,289
8	Other Comprehensive Income						
	(i) Items that will not be reclassified to Profit or (Loss)	(2,442)	(2,801)	(1,613)	(784)	(723)	(6,409)
	(ii) Income tax relating to items that will not be reclassified to Profit or (Loss)	349	(354)	184	(514)	98	747
9	Total Comprehensive Income/(Loss) for the Period	476	4,505	(300)	10,613	6,596	3,627
10	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64	5,135.64	5,135.64
11	Other Equity (excluding Revaluation Reserve)						48,231
12	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	1.00	2.98	0.44	4.64	2.81	3.62



Alembic Limited
Segment wise Standalone Revenue and Results

Rs. in Lakhs

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2024 (Unaudited)	30.09.2024 (Unaudited)	31.12.2023 (Unaudited)	31.12.2024 (Unaudited)	31.12.2023 (Unaudited)	31.03.2024 (Audited)
1	Segment Revenue						
	Revenue from Operations						
	a. Active Pharmaceutical Ingredients Business	625	746	648	2,443	2,377	3,174
	b. Real Estate Business	4,971	4,364	3,146	13,171	8,097	12,051
	Total Income from Operations (Net)	5,597	5,110	3,794	15,614	10,474	15,225
2	Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)						
	a. Active Pharmaceutical Ingredients Business	199	36	101	285	238	336
	b. Real Estate Business	2,463	1,674	1,106	5,967	2,815	5,087
	Total	2,661	1,710	1,207	6,252	3,052	5,423
	Unallocable Income and Expenditure						
	(i) Interest Expense	(52)	(51)	(26)	(138)	(36)	(69)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	54	6,398	70	6,484	4,845	4,869
	(iii) Other Income / (Expense)	22	30	1	32	49	49
	Total Profit Before Tax	2,685	8,087	1,253	12,631	7,910	10,272
3	Segment Assets						
	a. Active Pharmaceutical Ingredients Business	18,645	18,215	18,301	18,645	18,301	18,380
	b. Real Estate Business	41,839	40,917	34,582	41,839	34,582	35,897
	c. Unallocated	42,198	44,564	45,874	42,198	45,874	40,310
	Total	1,02,682	1,03,697	98,758	1,02,682	98,758	94,587
4	Segment Liabilities						
	a. Active Pharmaceutical Ingredients Business	3,464	3,291	2,915	3,464	2,915	2,941
	b. Real Estate Business	10,050	11,264	8,205	10,050	8,205	6,941
	c. Unallocated	3,841	4,291	3,793	3,841	3,793	3,829
	Total	17,355	18,846	14,913	17,355	14,913	13,711

Notes:

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

Place : Vadodara
Date : 7th February, 2025



For Alembic Limited

Chirayu Amin
Chairman

Independent Auditor's Review Report on Unaudited Consolidated Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)


To the Board of Directors of Alembic Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Alembic Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 31st December, 2024 and year to date from 01st April, 2024 to 31st December, 2024 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable.

4. Emphasis of Matter

We draw attention to the status of disputed liability related to pending electricity duty matter. During the previous periods, the Company had made aggregate provision towards total principal amount being Rs. 2,052.13 lakhs for the disputed matter(s) filed against State of Gujarat, Collector of Electricity Duty & others. The interest amount thereon is not ascertainable and is disclosed as contingent liability in the Consolidated Financial Statements for the year ended 31st



The Nirat, 3rd Floor, 18, Winward Business Park, Behind Emerald One Complex, In the lane of Dr. Prasant Buch's Hospital, Jetalpur, Vadodara 390 007. Tel: +91 265 234 3483

Website: www.cnkindia.com

March, 2024. Further, the Company has deposited Rs. 35 Crores with the Hon'ble Supreme Court on 26th May, 2023 and the appeal filed by the Company has been admitted.

Our opinion is not modified in respect of above matter.

5. The statement includes results of the following entities:
 - i. Alembic City Limited (Subsidiary)
 - ii. Alembic Pharmaceuticals Limited (Associate)
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We did not review the financial result of a subsidiary included in the unaudited consolidated financial results, whose unaudited financial results reflect total revenue of Rs.963.74 lakhs and Rs. 2,780.76 lakhs, total net loss after tax of Rs. 64.76 lakhs and Rs. 158.61 lakhs and total comprehensive loss of Rs. 64.91 lakhs and Rs. 158.57 lakhs for the quarter ended 31st December, 2024 and the period ended on that day respectively. The unaudited consolidated financial results also include the Group's share of net profit after tax of Rs. 3,929.86 lakhs and Rs. 12,140.33 lakhs and total comprehensive income of Rs. 3,987.23 lakhs and Rs. 12,139.48 lakhs for the quarter ended 31st December, 2024 and the period ended on that day respectively, as considered in the statement, in respect of an associate. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of a subsidiary and associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on statement is not modified with respect of the above matter.

For CNK & Associates LLP

Chartered Accountants

Firm Registration No. 101961W/W-100036

Rachit Sheth

Rachit Sheth

Partner

Membership No.158289

Place: Vadodara

Date: 07th February, 2025

UDIN: 25158289BMHZSB9647




Independent Auditor's Review Report on Unaudited Standalone Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial results of Alembic Limited ("the Company") for the quarter ended 31st December, 2024 and year to date from 01st April, 2024 to 31st December, 2024 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. **Emphasis of Matter**

We draw attention to the status of disputed liability related to pending electricity duty matter. During the previous periods, the Company had made aggregate provision towards total principal amount being Rs. 2,052.13 lakhs for the disputed matter(s) filed against State of Gujarat, Collector of Electricity Duty & others. The interest amount thereon is not



The Nirat, 3rd Floor, 18, Winward Business Park, Behind Emerald One Complex, In the lane of Dr. Prasant Buch's Hospital, Jetalpur, Vadodara 390 007. Tel: +91 265 234 3483

Website: www.cnkindia.com

ascertainable and is disclosed as contingent liability in the Standalone Financial Statements for the year ended 31st March, 2024. Further, the Company has deposited Rs. 35 Crores with the Hon'ble Supreme Court on 26th May, 2023 and the appeal filed by the Company has been admitted.

Our opinion is not modified in respect of above matter.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited standalone financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For CNK & Associates LLP
Chartered Accountants
Firm Registration No. 101961W/W-100036

Rachit
Rachit Sheth
Partner
Membership No.158289
Place: Vadodara
Date: 07th February, 2025
UDIN: 25158289BMHZSA6340



- B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC. – **Not Applicable.**

- C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES – **Not Applicable. No default.**

- D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter) - **Not Applicable.**

- E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) - **Not Applicable.**